|
|
|
Insider
Information: |
Mario Ernest |
Relationship: |
Director |
City: |
Redwood City |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
13 |
|
Direct
Shares |
1,089,697 |
|
Indirect Shares
|
264,473 |
|
|
Direct
Value |
$8,309,557 |
|
|
Indirect Value
|
$120,004 |
|
|
Total
Shares |
1,354,170 |
|
|
Total
Value |
$8,429,560 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
3
|
0
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
2
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-41.7%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Maxygen Inc |
MAXY |
Director |
2012-06-06 |
62,964 |
2003-08-05 |
0 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director |
2004-05-05 |
70,431 |
2004-05-05 |
85,554 |
Premium* |
|
Pharmaceutical Product Developme... |
PPDI |
Director |
2011-12-05 |
0 |
2011-12-05 |
0 |
Premium* |
|
Boston Scientific Corp |
BSX |
Director |
2015-11-16 |
86,032 |
2013-11-08 |
0 |
Premium* |
|
Alexza Pharmaceuticals Inc. |
ALXA |
Director |
2006-03-08 |
18,181 |
|
0 |
Premium* |
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
Vivus Inc |
VVUS |
Director |
2013-05-29 |
81,125 |
2012-04-25 |
0 |
Premium* |
|
Xenoport Inc |
XNPT |
Director |
2015-05-19 |
88,750 |
2012-08-09 |
0 |
Premium* |
|
Tonix Pharmaceuticals Holding Corp |
TNXP |
Director |
2018-02-09 |
0 |
2018-06-25 |
50,000 |
Premium* |
|
Chimerix Inc |
CMRX |
Director |
2018-05-18 |
12,905 |
2018-05-18 |
108,167 |
Premium* |
|
Kindred Biosciences, Inc. |
KIN |
Director |
2018-10-29 |
169,000 |
2013-12-12 |
0 |
Premium* |
|
Soleno Therapeutics Inc |
SLNO |
Director |
2024-01-08 |
124,566 |
2024-01-08 |
20,752 |
Premium* |
|
Eyenovia Inc |
EYEN |
Director |
2021-01-15 |
375,743 |
2018-07-24 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
372 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 14 of 15
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CMRX |
Chimerix Inc |
Director |
|
2016-12-27 |
4 |
AS |
$4.65 |
$354,050 |
I/I |
(75,709) |
292,826 |
0 |
- |
|
CELG |
Celgene Corp |
Director |
|
2013-10-24 |
4 |
OE |
$59.89 |
$359,340 |
D/D |
6,000 |
91,671 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2005-04-28 |
4 |
S |
$46.00 |
$385,763 |
I/I |
(8,381) |
479,161 |
|
- |
|
CELG |
Celgene Corp |
Director |
|
2014-02-04 |
4 |
OE |
$60.02 |
$420,140 |
D/D |
7,000 |
100,671 |
0 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2009-05-06 |
4 |
B |
$8.49 |
$424,650 |
D/D |
50,000 |
71,004 |
2.39 |
- |
|
CELG |
Celgene Corp |
Director |
|
2017-10-30 |
4 |
OE |
$31.80 |
$432,412 |
D/D |
13,600 |
71,024 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2009-12-17 |
4 |
OE |
$13.58 |
$458,240 |
D/D |
32,000 |
160,434 |
0 |
- |
|
CELG |
Celgene Corp |
|
|
2018-12-19 |
4 |
OE |
$59.06 |
$507,873 |
D/D |
8,600 |
63,013 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2005-11-09 |
4 |
S |
$58.50 |
$526,500 |
I/I |
(9,000) |
428,842 |
|
- |
|
CELG |
Celgene Corp |
Director |
|
2016-02-01 |
4 |
OE |
$29.00 |
$539,400 |
D/D |
18,600 |
101,049 |
0 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2011-11-28 |
4 |
B |
$5.40 |
$540,000 |
D/D |
100,000 |
407,304 |
2.39 |
- |
|
CELG |
Celgene Corp |
Director |
|
2010-05-24 |
4 |
B |
$55.49 |
$554,934 |
D/D |
10,000 |
20,000 |
2.39 |
- |
|
CELG |
Celgene Corp |
|
|
2018-11-26 |
4 |
OE |
$59.06 |
$590,550 |
D/D |
10,000 |
54,413 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2007-08-09 |
4 |
S |
$38.68 |
$619,080 |
D/D |
(16,000) |
434,669 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2010-08-09 |
4 |
S |
$25.12 |
$671,357 |
D/D |
(26,726) |
160,433 |
0 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2011-08-02 |
4 |
B |
$6.82 |
$682,230 |
D/D |
100,000 |
231,004 |
2.39 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2005-05-03 |
4 |
S |
$46.54 |
$698,100 |
I/I |
(15,000) |
462,542 |
|
- |
|
CELG |
Celgene Corp |
Director |
|
2014-02-05 |
4 |
OE |
$59.89 |
$845,761 |
D/D |
13,500 |
114,171 |
0 |
- |
|
CMRX |
Chimerix Inc |
Director |
|
2015-12-29 |
4 |
B |
$7.09 |
$886,613 |
D/D |
125,000 |
262,637 |
2.39 |
- |
|
CELG |
Celgene Corp |
Director |
|
2013-06-05 |
4 |
OE |
$59.89 |
$898,350 |
D/D |
15,000 |
80,013 |
0 |
- |
|
EYEN |
Eyenovia Inc |
Director |
|
2018-01-29 |
4 |
B |
$10.00 |
$900,000 |
D/D |
90,000 |
236,770 |
2.39 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2015-05-18 |
4 |
S |
$18.09 |
$904,630 |
D/D |
(50,000) |
211,032 |
0 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2007-08-21 |
4 |
S |
$12.16 |
$934,911 |
D/D |
(76,767) |
64,700 |
0 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2006-05-10 |
4 |
B |
$21.30 |
$1,067,377 |
I/I |
50,000 |
50,000 |
2.1 |
- |
|
CELG |
Celgene Corp |
|
|
2018-08-09 |
4 |
S |
$92.32 |
$1,107,888 |
D/D |
(12,000) |
44,413 |
0 |
- |
|
372 Records found
|
|
Page 14 of 15 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|